MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer

Archives of Medical Science

Volumn 11, Issue 3, 2015, Pages 561-569

  Lan, Gongbin ^a   Yang, Luoyan ^a   Xie, Xubiao ^a   Peng, Longkai ^a   Wang, Yi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bladder cancer; c FOS; miR 490 5p; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 490 5P; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; DOWN REGULATION; GAIN OF FUNCTION MUTATION; GENE CONTROL; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MTT ASSAY; ONCOGENE C FOS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84932170864     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.52359     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Kakizoe T, Mucci LA, Albertsen PC, Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urol Nephrol Suppl 2008; 218: 191-212.
3. Donat SM. Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J Natl Compr Canc Netw 2009; 7: 40-7.
4. Nese N, Gupta R, Bui MH, Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw 2009; 7: 48-57.
5. Rochester MA, Patel N, Turney BW, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 2007; 100: 1396-401.
6. Wang CC, Chiang YM, Kuo PL, Chang JK, Hsu YL. Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells byarresting the cell cycle at the G0/G1 phase and inducing a Fas/membrane-bound Fasligand-mediated apoptotic pathway. Clin Exp Pharmacol Physiol 2008; 35: 1301-8.
7. May M, Helke C, Nitzke T, Vogler H, Hoschke B. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int 2004; 72: 103-11.
8. Aglamis E, Toktas G, Unluer E, et al. Prognostic factors in radical cystectomy affecting survival. Arch Med Sci 2012; 8: 650-4.
9. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008; 99: 646-52.
10. Jabłonowski Z, Reszka E, Gromadzińska J, et al. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci 2011; 7: 512-6.
11. Chow TF, Mankaruos M, Scorilas A, et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010; 183: 743-51.
12. Visone R, Veronese A, Rassenti LZ, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011; 118: 3072-9.
13. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18: 181-7.
14. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
16. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-14.
17. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-73.
18. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-71.
19. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009; 69: 4851-60.
20. Noguchi S, Mori T, Hoshino Y, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307: 211-20.
21. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL, Dahiya R. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 2012; 33: 41-8.
22. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011; 102: 522-9.
23. Han Y, Chen J, Zhao X, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011; 6: e18286.
24. Schmittgen TD, Lee EJ, Jiang J, et al. Real-time PCR quantification of precursor and mature microRNA. Methods 2008; 44: 31-8.
25. Griffiths-Jones S, Grocock RJ, van DS, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34 (Database issue): D140-4.
26. Wilmott JS, Zhang XD, Hersey P, Scolyer RA. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology 2011; 43: 657-71.
27. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-92.
28. Meiri E, Levy A, Benjamin H, et al. Discovery of microRNAs and other small RNAs in solid tumors. Nucleic Acids Res 2010; 38: 6234-46.
29. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009; 124: 2236-42.
30. Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009; 46: 497-510.
31. Durchdewald M, Angel P, Hess J. The transcription factor Fos: a Janus-type regulator in health and disease. Histol Histopathol 2009; 24: 1451-61.
32. Yao HQ, Peng Y, Zhong ZZ, He HX, Li ZH. Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 177-9.